# Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking

> **NCT00218465** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 264 (actual)

## Conditions studied

- Nicotine Dependence

## Interventions

- **DRUG:** GW468816
- **DRUG:** Placebo Comparator: Placebo

## Key facts

- **NCT ID:** NCT00218465
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2017-03-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00218465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00218465, "Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00218465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*